# Drug-Drug Interaction Study: ASP2151 and Ritonavir

> **NCT02223351** · PHASE1 · COMPLETED · sponsor: **Maruho Europe Limited** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ASP2151
- **DRUG:** ritonavir

## Key facts

- **NCT ID:** NCT02223351
- **Lead sponsor:** Maruho Europe Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223351, "Drug-Drug Interaction Study: ASP2151 and Ritonavir". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02223351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*